E25Bio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Out of Business

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Out of Business

E25Bio General Information

Description

Developer of a paper-based diagnostic platform designed to effectively facilitate epidemiologic predictions and disease mapping. The company's platform offers multiplexed tests that can swiftly detect viral antigens produced during infection, results of which can be captured by a mobile phone application for real-time data reporting and analytics, enabling governments to accurately identify zika virus, dengue, and chikungunya, and novel coronavirus at the point of care at an affordable cost and effectively prevent an outbreak from turning into a public health crisis.

Contact Information

Website
www.e25bio.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 501 Massachusetts Avenue
  • Office 221
  • Cambridge, MA 02139
  • United States
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Biotechnology
Vertical(s)
Digital Health, HealthTech, Mobile
Corporate Office
  • 501 Massachusetts Avenue
  • Office 221
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

E25Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Out of Business 27-Jan-2023 Completed Out of Business
10. Early Stage VC 31-May-2021 Completed Generating Revenue
9. Grant 13-Aug-2020 Completed Generating Revenue
8. Early Stage VC 19-May-2020 Completed Generating Revenue
7. Accelerator/Incubator 01-Jan-2020 Completed Generating Revenue
6. Grant 01-Jan-2020 Completed Generating Revenue
5. Seed Round 12-Aug-2019 Completed Generating Revenue
4. Grant 10-Aug-2019 Completed Generating Revenue
3. Grant 01-Jan-2019 $151K Completed Generating Revenue
2. Seed Round 01-Dec-2018 Completed Generating Revenue
To view E25Bio’s complete valuation and funding history, request access »

E25Bio Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Seed-1
Seed-3
Seed-2 50,171 $0.000100 $4.98 $4.98 1x $4.98 3.75%
To view E25Bio’s complete cap table history, request access »

E25Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a paper-based diagnostic platform designed to effectively facilitate epidemiologic predictions and disease
Diagnostic Equipment
Cambridge, MA
7 As of 2022

London, United Kingdom
 

Uppsala, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

E25Bio Competitors (20)

One of E25Bio’s 20 competitors is DNAe, a Formerly VC-backed company based in London, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DNAe Formerly VC-backed London, United Kingdom
Q-linea Formerly VC-backed Uppsala, Sweden
Epic Sciences Venture Capital-Backed San Diego, CA
Autogenomics Formerly VC-backed Carlsbad, CA
Cepheid Formerly VC-backed Sunnyvale, CA
You’re viewing 5 of 20 competitors. Get the full list »

E25Bio Patents

  • 5

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • Pending

  • Expiring in next 12 mo

E25Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022010736-A1 High throughput screening for monoclonal antibody pairs Inactive 08-Jul-2020
WO-2021222597-A2 Rapid diagnostic immunoassay for presence of antibodies Inactive 30-Apr-2020
WO-2021222597-A3 Rapid diagnostic immunoassay for presence of antibodies Inactive 30-Apr-2020
WO-2021194980-A2 Rapid diagnostic immunoassay for presence of viral antigen Inactive 23-Mar-2020
WO-2021194980-A3 Rapid diagnostic immunoassay for presence of viral antigen Inactive 23-Mar-2020 G01N33/56983
To view E25Bio’s complete patent history, request access »

E25Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

E25Bio FAQs

  • When was E25Bio founded?

    E25Bio was founded in 2018.

  • Where is E25Bio headquartered?

    E25Bio is headquartered in Cambridge, MA.

  • What is the size of E25Bio?

    E25Bio has 7 total employees.

  • What industry is E25Bio in?

    E25Bio’s primary industry is Diagnostic Equipment.

  • Is E25Bio a private or public company?

    E25Bio is a Private company.

  • What is E25Bio’s current revenue?

    The current revenue for E25Bio is .

  • How much funding has E25Bio raised over time?

    E25Bio has raised $6.8M.

  • Who are E25Bio’s competitors?

    DNAe, Q-linea, Epic Sciences, Autogenomics, and Cepheid are some of the 20 competitors of E25Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process